AVERROES Study Closes Early Due to Clear Evidence of Efficacy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation.
Ranbaxy Launches Antiplatelet Agent Prasugrel in India
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced today that Ranbaxy has launched a generic version of prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Americans Are Not Taking Action to Protect Themselves Against Muscle Loss
- Details
- Category: Abbott
Nearly nine in 10 people think feeling weaker is one of the worst parts about aging, according to a recent survey commissioned by Abbott and developed in conjunction with the AGS Foundation for Health in Aging, a nonprofit dedicated to the health and well-being of older adults, which provided expert, independent review.
Sanofi Pasteur Partners with Vivalis for the Discovery of Human Monoclonal Antibodies
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced the signature with Vivalis (NYSE and Euronext: VLS) of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases.
Merck Resubmits U.S. Application for Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Cladribine Tablets as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).
Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening compared to chemotherapy alone.
Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care
- Details
- Category: Pfizer
Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.(1)
More Pharma News ...
- Merck Announces Launch of Pioneering Collaborative Cancer Trials Network
- FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis
- Victoza® to be launched in Japan in June
- AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Application
- Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan
- Novartis announces extension of US regulatory priority review period for FTY720
- Results of the clinical study CALYPSO Published in The Journal of Clinical Oncology